Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma, Alveolar 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Mesothelioma, Malignant 1Lymphoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1

Interventions

Cyclophosphamide 26Rituximab 22Biopsy 17Specimen Handling 16Prednisone 15Magnetic Resonance Spectroscopy 14Doxorubicin 14fludarabine 12Vincristine 12fludarabine phosphate 9Etoposide 7Bendamustine Hydrochloride 7Tacrolimus 6Nuclear Medicine Department, Hospital 6Melphalan 6trametinib 5acalabrutinib 5X-Rays 5Whole-Body Irradiation 5Radiotherapy 5Mycophenolic Acid 5Lenalidomide 5Crizotinib 5pembrolizumab 4ibrutinib 4copanlisib 4Prednisolone 4Mesna 4Dexamethasone 4Cytarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma × BAY 1895344 × Clear all
NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
31 enrolled 14 charts
LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡